DK1626736T3 - C1-inhibitor med kort halveringstid til midlertidig behandling - Google Patents

C1-inhibitor med kort halveringstid til midlertidig behandling Download PDF

Info

Publication number
DK1626736T3
DK1626736T3 DK04748575.0T DK04748575T DK1626736T3 DK 1626736 T3 DK1626736 T3 DK 1626736T3 DK 04748575 T DK04748575 T DK 04748575T DK 1626736 T3 DK1626736 T3 DK 1626736T3
Authority
DK
Denmark
Prior art keywords
inhibitor
life
short half
temporary treatment
temporary
Prior art date
Application number
DK04748575.0T
Other languages
English (en)
Inventor
Johannes Henricus Nuijens
Original Assignee
Pharming Intellectual Property B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B V filed Critical Pharming Intellectual Property B V
Application granted granted Critical
Publication of DK1626736T3 publication Critical patent/DK1626736T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04748575.0T 2003-05-16 2004-05-14 C1-inhibitor med kort halveringstid til midlertidig behandling DK1626736T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03076466 2003-05-16
PCT/NL2004/000330 WO2004100982A1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life for transient treatment

Publications (1)

Publication Number Publication Date
DK1626736T3 true DK1626736T3 (da) 2020-09-28

Family

ID=33442800

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04748575.0T DK1626736T3 (da) 2003-05-16 2004-05-14 C1-inhibitor med kort halveringstid til midlertidig behandling

Country Status (15)

Country Link
US (2) US7544853B2 (da)
EP (1) EP1626736B1 (da)
JP (1) JP2007500741A (da)
CN (1) CN100431604C (da)
AU (1) AU2004238170B2 (da)
CA (1) CA2525522A1 (da)
CY (1) CY1123601T1 (da)
DK (1) DK1626736T3 (da)
ES (1) ES2830499T3 (da)
HU (1) HUE052154T2 (da)
NZ (1) NZ543646A (da)
PL (1) PL1626736T3 (da)
PT (1) PT1626736T (da)
SI (1) SI1626736T1 (da)
WO (1) WO2004100982A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502539A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
BRPI0519349A8 (pt) 2004-12-23 2017-09-12 Csl Behring Gmbh Prevenção de formação e/ou estabilização de trombos
CN105641688B (zh) * 2005-12-21 2020-06-09 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
ATE516043T1 (de) * 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
JP2010505946A (ja) * 2006-10-10 2010-02-25 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 神経再生改善のための補体阻害
CA2829037C (en) * 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EA201500526A1 (ru) * 2012-11-13 2015-12-30 Общество С Ограниченной Ответственностью "Биогениус Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения
US10441631B2 (en) * 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
KR102430453B1 (ko) 2013-03-15 2022-08-05 바이로파마 바이오로직스 엘엘씨 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
US20150104445A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
US20160361394A1 (en) * 2014-02-28 2016-12-15 Santarus, Inc. Treatment of hereditary angioedema with c1 inhibitor
AU2019226355A1 (en) * 2018-02-28 2020-09-17 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3895726A1 (en) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
JPH05503001A (ja) 1989-10-27 1993-05-27 スティッチング セントラール ラボラトリウム ファン デ ブルートトランスフュジエディエンスト ファン ヘット ネデールランツェ ローデ クルイス C1インヒビターミューティンおよびその利用
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US6713662B1 (en) 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
CA2398707C (en) * 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7229665B2 (en) * 2001-05-22 2007-06-12 Millipore Corporation Process of forming multilayered structures
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment

Also Published As

Publication number Publication date
AU2004238170A1 (en) 2004-11-25
USRE43691E1 (en) 2012-09-25
US7544853B2 (en) 2009-06-09
CN1791425A (zh) 2006-06-21
NZ543646A (en) 2009-09-25
ES2830499T3 (es) 2021-06-03
WO2004100982A1 (en) 2004-11-25
SI1626736T1 (sl) 2021-04-30
AU2004238170B2 (en) 2009-11-05
CY1123601T1 (el) 2022-03-24
CN100431604C (zh) 2008-11-12
US20070185011A1 (en) 2007-08-09
EP1626736B1 (en) 2020-09-16
EP1626736A1 (en) 2006-02-22
JP2007500741A (ja) 2007-01-18
PT1626736T (pt) 2020-10-13
HUE052154T2 (hu) 2021-04-28
CA2525522A1 (en) 2004-11-25
PL1626736T3 (pl) 2021-05-04

Similar Documents

Publication Publication Date Title
DK1626736T3 (da) C1-inhibitor med kort halveringstid til midlertidig behandling
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE413395T1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitor n
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DE60323899D1 (de) Startvorrichtung
ATE333271T1 (de) Uv-stabiles transdermales pflaster
DE602004032551D1 (de) Hren dafür
DE602004018746D1 (de) Hren dafür
DE60327447D1 (de) Pflaster
DE602004018936D1 (de) Härtbare zusammensetzung
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
DE602004027413D1 (de) Hren dafür
DE50307776D1 (de) Rohrschelle
ATA14732002A (de) Spannvorrichtung
FI20021531A (fi) Muurausmenetelmä
DE502004001560D1 (de) Kaltarbeitsstahl-Gegenstand
FI20031408A0 (fi) Säilöntälaitteisto
DE60307471D1 (de) Hemmung
DE502004011330D1 (de) Spannvorrichtung
ATA19362002A (de) Verlorene schalung
NO20022243D0 (no) Fremgangsmåte for rörlegging
DE50302056D1 (de) Kreuzklemmvorrichtung
ATA9422004A (de) Verbissschutz
ATA2722003A (de) Schalung
DE50302930D1 (de) Startvorrichtung